Skip to main content
TipRanks
Go Ultimate75% OFF

Sagimet Biosciences, Inc. Class A (SGMT) AI Stock Analysis

1,730 Followers
SGMT

Sagimet Biosciences, Inc. Class A

(NASDAQ:SGMT)

Select Model
Rating:58Neutral
Price Target:$11.50▲(16.75% Upside)
Action:reiterated
Date:11/13/26

SGMT’s score is held back most by weak financial performance (minimal revenue, large ongoing losses, and persistent cash burn) despite a strengthened, low-debt balance sheet. Offsetting this, technicals are supportive with the stock trading above key moving averages and positive momentum, and corporate events are favorable with Phase 3/regulatory progress and substantial new financing improving funding runway. Valuation contributes only moderately given the negative P/E and lack of dividend yield data.

Positive Factors
Extended funding runwayThe substantial cash balance and recent financing materially extend Sagimet’s ability to fund clinical development without relying immediately on additional capital. This supports continuity across Phase 3 programs, regulatory preparation, and follow-on pipeline work over the next several quarters.
Negative Factors
Pre-commercial revenue baseSagimet currently lacks a marketed-product revenue stream to support operations, leaving its financial outlook dependent on clinical success, financing, and potential partnering. Until commercialization occurs, revenue visibility and operating leverage remain limited over the medium term.

Sagimet Biosciences, Inc. Class A (SGMT) vs. SPDR S&P 500 ETF (SPY)

-40%-20%0%20%40%60%SGMT+35.49%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$712.56M
Dividend Yield
―
Average Volume (3M)
1.24M
Price to Earnings (P/E)
-8.6
Beta (1Y)
2.64
Revenue Growth
―
EPS Growth
33.38%
Country
US
Employees
16
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Sagimet Biosciences, Inc. Class A Business Overview & Revenue Model

Company Description

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United...

How the Company Makes Money

Sagimet Biosciences does not have publicly known material recurring revenue from marketed products; as a clinical-stage biotechnology company, its ability to generate revenue is primarily tied to financing and partnering activities rather than produc...

Sagimet Biosciences, Inc. Class A Financial Statement Overview

Summary

Overall fundamentals are mixed: the balance sheet is a clear strength with very low leverage (debt-to-equity near zero) and meaningfully improved equity, but the company remains pre-commercial with minimal revenue, persistent and widening net losses (TTM net loss about -$53.3M), and sustained negative operating/free cash flow indicating ongoing cash burn and funding needs.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue0002.00M00
Gross Profit-21.57M002.00M00
EBITDA-55.94M-51.04M-45.57M-27.88M-30.37M-24.44M
Net Income-53.32M-51.04M-45.57M-27.88M-30.50M-24.44M
Balance Sheet
Total Assets282.09M116.48M160.26M96.72M33.03M59.03M
Cash, Cash Equivalents and Short-Term Investments236.40M113.12M151.25M94.90M32.34M56.73M
Total Debt2.02M78.00K78.00K65.00K211.00K348.00K
Total Liabilities39.91M5.10M4.45M5.65M219.98M217.29M
Stockholders Equity242.18M111.38M155.81M91.06M-186.95M-158.26M
Cash Flow
Free Cash Flow-43.25M-45.65M-42.44M-23.77M-24.49M-21.71M
Operating Cash Flow-43.25M-45.65M-42.44M-23.77M-24.49M-21.71M
Investing Cash Flow-72.69M4.56M-61.68M12.58M-32.01M0
Financing Cash Flow369.81M275.00K104.82M86.17M-73.00K9.74M

Sagimet Biosciences, Inc. Class A Technical Analysis

Technical Analysis SentimentNeutral
Last Price9.85

Price Trends

50DMA9.86Positive
100DMA9.26Positive
200DMA7.73Positive

Market Momentum

MACD0.28Negative
RSI51.03Neutral
STOCH58.13Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMT, the sentiment is Neutral. The current price of 9.85 is below the 20-day moving average (MA) of 10.17, below the 50-day MA of 9.86, and above the 200-day MA of 7.73, indicating a neutral trend. The MACD of 0.28 indicates Negative momentum. The RSI at 51.03 is Neutral, neither overbought nor oversold. The STOCH value of 58.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SGMT.

Sagimet Biosciences, Inc. Class A Risk Analysis

Sagimet Biosciences, Inc. Class A disclosed 78 risk factors in its most recent earnings report. Sagimet Biosciences, Inc. Class A reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Our business may be materially adversely affected by the imposition of tariffs and other trade barriers and retaliatory countermeasures implemented by the United States and other governments.Q1, 2025
2.Although we have received Breakthrough Therapy designation for denifanstat, this may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood of receiving marketing approval in the United States.Q4, 2024
3.The use of new and evolving technologies, such as AI, in our business may result in spending material resources and presents risks and challenges that can impact our business including by posing security and other risks to our confidential and/or proprietary information, including personal information, and as a result we may be exposed to reputational harm and liability.Q4, 2024

Sagimet Biosciences, Inc. Class A Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SGMT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SGMTSGMT58Neutral$712.56M-8.57-29.95%――33.38%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AVIRAVIR48Neutral$330.85M-2.13-69.92%――-10.43%
CDXSCDXS45Neutral$116.17M-5.43-43.24%―66.89%73.74%
CABACABA41Neutral$239.45M-0.78-106.78%――43.51%
BDTXBDTX39Underperform$87.93M-1.95-43.99%―-100.00%-302.37%
TRDATRDA39Underperform$195.75M-1.32-64.00%―-93.54%-53.55%

* Healthcare Sector Average

Performance Comparison

-50%0%50%SGMTCDXSCABABDTXAVIRTRDADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SGMT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SGMTSagimet Biosciences, Inc. Class A9.852.0025.48%
CDXSCodexis1.07-0.55-33.95%
CABACabaletta Bio, Inc.1.02-1.22-54.46%
BDTXBlack Diamond Therapeutics, Inc.1.44-2.45-62.98%
AVIRAtea Pharmaceuticals, Inc.3.960.8125.71%
TRDAEntrada Therapeutics Inc4.96-3.77-43.18%

Sagimet Biosciences, Inc. Class A Corporate Events

Financial DisclosuresPrivate Placements and FinancingProduct-Related Announcements

Sagimet Biosciences Reports Third-Quarter Financial Results and R&D Growth

Positive
Nov 12, 2026

On November 12, 2026, Sagimet reported a net loss of $19.1 million for the third quarter and $43.8 million for the first nine months, compared with $12.9 million and $41.5 million, respectively, a year earlier. Research and development expense rose t...

Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance

Sagimet Biosciences Highlights Progress in Acne FASN Pipeline

Positive
Oct 22, 2026

On October 22, 2026, Sagimet Biosciences updated its investor slide presentation to highlight progress across its FASN inhibitor pipeline, led by denifanstat for moderate to severe acne. The company emphasized its experienced management team and diff...

Business Operations and StrategyPrivate Placements and Financing

Sagimet Biosciences Announces Major Equity Financing Agreement

Positive
Oct 1, 2026

On September 30, 2026, Sagimet Biosciences Inc. entered into an underwriting agreement for an underwritten offering of 8,750,010 shares of Series A common stock at $10.00 per share and pre-funded warrants to purchase up to 2,750,010 shares at $9.9999...

Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance

Sagimet Reports Strong Phase 3 Acne Trial Results

Positive
Sep 30, 2026

On September 30, 2026, Sagimet Biosciences reported positive 52-week results from the Phase 3 ASC40-304 open-label extension trial of denifanstat in patients with moderate to severe acne vulgaris in China, showing further improvements in lesion count...

Business Operations and StrategyRegulatory Filings and Compliance

Sagimet Wins FDA Clearance for Phase 3 Acne Trial

Positive
Aug 13, 2026

On August 13, 2026, Sagimet Biosciences Inc. announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for denifanstat. The agency issued a “Study May Proceed” letter, allowing the company to begin a Phase...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026